plans for analysis of patient level data for pediatric studies psychopharmacologic drugs advisory...
TRANSCRIPT
![Page 1: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/1.jpg)
Plans for Analysis of Patient Level Data for Pediatric Studies
Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee
February 2, 2004
Tarek A. Hammad, MD, PhD, MSc, MS
Medical Reviewer
Division of Neuropharmacological Drug Products Center for Drug Evaluation and Research, FDA
![Page 2: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/2.jpg)
Outline
• Objective• Data
– Drugs and Indications – Individual Patients Data– Challenges with Available Data
• Analysis Plan– Exploratory Analysis
• Univariate Analysis
• Crude Analysis
– Estimate of Overall Effect– Sensitivity Analysis– Limitations on Interpretation of Data
2 2
![Page 3: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/3.jpg)
Objective • To evaluate the risk of suicidality associated
with the use of antidepressants in pediatric patients using the results of the blinded re-classification of cases
– We will address possible sources of imbalance in the data e.g. trial design, duration of exposure, patient population, and other potential confounders
– Understand the sources of inconsistency between trials or between drugs, if any
![Page 4: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/4.jpg)
Outline
• Objective• Data
– Drugs and Indications – Individual Patients Data– Challenges with Available Data
• Analysis Plan– Exploratory Analysis
• Univariate Analysis
• Crude Analysis
– Estimate of Overall Effect– Sensitivity Analysis– Limitations on Interpretation of Data
4 4
![Page 5: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/5.jpg)
Data• Controlled trials conducted in pediatric
patients in nine drug development programs
• Drugs - number of trials: – SSRIs group
• Fluoxetine (Prozac) - 4• Sertraline (Zoloft) - 3• Paroxetine (Paxil) - 6 • Fluvoxamine (Luvox) - 1 • Citalopram (Celexa) - 2
– Atypical antidepressants group• Bupropion (Wellbutrin) - 2• Venlafaxine (Effexor) - 4 • Nefazodone (Serzone) - 2• Mirtazapine (Remeron) - 1 5 5
![Page 6: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/6.jpg)
Data, continued ...
• Indications - number of trials
– Major Depressive Disorder - 15– Anxiety Disorders
• Obsessive Compulsive Disorder - 5• Generalized Anxiety Disorder - 2 • Social anxiety Disorder/Social Phobia - 1
– Attention Deficit Hyperactivity Disorder - 2
6 6
![Page 7: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/7.jpg)
7 7
Variable name Length Type Description Coding notes TRIAL NS Character Trial ID No missing values
are allowed in this variable.
CTPID NS Character Patient ID within each trial.
No missing values are allowed in this variable
UNIQUEID NS Character A unique ID for every patient
It should incorporate both the trial ID and the patient ID within each trial. No missing values are allowed in this variable.
DIAG NS Character Condition for which patient was being treated
No missing values are allowed in this variable.
• Individual patients data:– Developed a standard format for electronic
datasets– Descriptive information about every trial
![Page 8: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/8.jpg)
• Demographics variables – Age, gender, race, and BMI– Location (North America vs. not)
– Setting (inpatient vs. outpatient vs. both)
• Disease-related variables– Diagnosis– Baseline severity score– Duration of illness prior to treatment
• Drug-related variables– Drug name – Maximum modal dose– Duration of treatment– Erratic compliance (defined as: not taking drug as prescribed during RCT)
8 8
Requested Variables
![Page 9: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/9.jpg)
• Outcome-related variables– First suicide-related event (FSE)– Time to FSE– If FSE occurred after discontinuation
• Psychiatric history variables – Prior history of:
o Suicide attempto Suicide ideationo Psychiatric hospitalizationo Substance abuseo Hostility or aggressive behavioro Irritability or agitation
• Treatment emergent adverse events– Agitation during RCT– Hostility during RCT 9 9
Requested Variables, continued ...
![Page 10: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/10.jpg)
Challenges with Available Data
• Quality-related component– Issues related to case ascertainment– Mechanism of data collection among
different trials/sponsors (10% rule)
• Analysis-related component– Trial vs. patient as the unit of analysis– Limitations of pooling data
10 10
![Page 11: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/11.jpg)
Trial vs. Patient as the Unit of Analysis
• Pooling of data from different trials treating them as one large trial fails to preserve the randomization effect and might introduce bias and confounding
• Maintaining the randomization guards against the foreseen (e.g. age and gender) and unforeseen (e.g. differences in medical practices or case ascertainment) imbalances between treatment groups
• The issue of trial similarity is not only pertinent to having the same protocol, but is also pertinent to the implementation of those protocols (implementation of criteria of inclusion and exclusion, patients care in reality…etc)
• Using trial as unit of analysis (meta-analysis) might result in loss of information
11 11
![Page 12: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/12.jpg)
Limitations of Pooling Data
• Compatibility of designs and patient populations, duration of treatment, and dose levels
• Class effect assumption– Implied by pooling drugs– Differences in size of databases
12 12
![Page 13: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/13.jpg)
Outline
• Objective• Data
– Drugs and Indications – Individual Patients Data– Challenges with Available Data
• Analysis Plan– Exploratory Analysis
• Univariate Analysis
• Crude Analysis
– Estimate of Overall Effect– Sensitivity Analysis– Limitations on Interpretation of Data
13 13
![Page 14: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/14.jpg)
Analysis Plan• Statistical computing – SAS, Stata, and JMP• Exploratory Analysis
– Univariate Analysis• Check data compliance & completeness• Check for coding error• Inspect the spread and shape of continuous
variables and frequencies of binary variables
– Crude Analysis• Risks and rates by drug, indication, and trial • Investigate complete separation and quasi-
complete separation• Investigate presence of interaction• Examine potential confounders
14 14
![Page 15: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/15.jpg)
Indication Drug Placebo Active ctrl
Indication I, overall
%
Rate
trial 1 %
Rate
trial 2 %
Rate
Indication II, overall
%
Rate
trial 3 %
Rate
trial 4 %
Rate
Analysis Plan, continued ...
Sample analysis table
15 15
![Page 16: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/16.jpg)
Analysis Plan, continued ...
• Estimate of overall effect– Trial as the Unit of Analysis (optimal):
• Adjust for confounders on trial level• Pool trials data for drug groups within indication groups• Exclude trials with no suicidality in both arms • Depending on the heterogeneity of the trials’ findings, the
variability between trials would be considered in a “fixed” effects or a “random” effects model
– Patient as the Unit of Analysis:• Poisson regression will be used to model rates of suicidality
adjusting for potential confounders• Pool patients data for drug groups within indication groups• Trials will be adjusted for as a random effect in the model
16 16
![Page 17: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/17.jpg)
Analysis Plan, continued ...
• Sensitivity Analysis
– The analysis will be stratified by the level of uncertainty to examine the robustness of the findings
![Page 18: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/18.jpg)
Limitations on Interpretation of Data• Our goal is to evaluate the risk of suicidality
associated with the use of antidepressants in pediatric patients
• Observed rates of suicidality might not reflect actual rates among patients in the general population
• Short-term exposure
• Informative censoring due to patterns of patients discontinuation no info
• It remains to be seen if we have enough statistical power to detect differences in the risk of suicidality among various drugs
![Page 19: Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective](https://reader036.vdocuments.mx/reader036/viewer/2022072016/56649efc5503460f94c0f6f4/html5/thumbnails/19.jpg)
In closing
• Those are our ideas and some of them were informed by our experience analyzing the data on completed suicides in adults
• Your feedback on our approach will be appreciated